CN1338943A - 利用vegf－c或vegf－d基因或蛋白预防再狭窄 - Google Patents

利用vegf－c或vegf－d基因或蛋白预防再狭窄 Download PDF

Info

Publication number
CN1338943A
CN1338943A CN99812544A CN99812544A CN1338943A CN 1338943 A CN1338943 A CN 1338943A CN 99812544 A CN99812544 A CN 99812544A CN 99812544 A CN99812544 A CN 99812544A CN 1338943 A CN1338943 A CN 1338943A
Authority
CN
China
Prior art keywords
vegf
polypeptide
polynucleotide
restenosis
blood vessel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99812544A
Other languages
English (en)
Chinese (zh)
Inventor
塞波·拉赫图亚拉
卡里·阿利塔洛
米科·O·希尔图南
马库·M·杰尔奇
马克·G·阿彻
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lisentia GmbH
Ludwig Institute for Cancer Research Ltd
Original Assignee
Lisentia GmbH
Ludwig Institute for Cancer Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lisentia GmbH, Ludwig Institute for Cancer Research Ltd filed Critical Lisentia GmbH
Publication of CN1338943A publication Critical patent/CN1338943A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN99812544A 1998-10-26 1999-10-26 利用vegf－c或vegf－d基因或蛋白预防再狭窄 Pending CN1338943A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10558798P 1998-10-26 1998-10-26
US60/105,587 1998-10-26

Publications (1)

Publication Number Publication Date
CN1338943A true CN1338943A (zh) 2002-03-06

Family

ID=22306672

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99812544A Pending CN1338943A (zh) 1998-10-26 1999-10-26 利用vegf－c或vegf－d基因或蛋白预防再狭窄

Country Status (12)

Country Link
EP (1) EP1126870B1 (enExample)
JP (2) JP4769929B2 (enExample)
CN (1) CN1338943A (enExample)
AT (1) ATE275417T1 (enExample)
AU (1) AU768330B2 (enExample)
CA (1) CA2340593C (enExample)
DE (1) DE69920031T2 (enExample)
ES (1) ES2229788T3 (enExample)
NO (1) NO20012017L (enExample)
NZ (1) NZ510121A (enExample)
PT (1) PT1126870E (enExample)
WO (1) WO2000024412A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101361988B (zh) * 2008-09-12 2011-12-21 西南交通大学 一种具有生物相容性的血管支架或心脏瓣膜表面涂层的制备方法
CN108640994A (zh) * 2018-06-28 2018-10-12 浙江众意生物科技有限公司 一种vegf-c单克隆抗体及试剂盒
CN119454907A (zh) * 2025-01-09 2025-02-18 浙江大学 Vegf-c156s在制备减轻静脉移植物狭窄的药物中的应用

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
JP4981229B2 (ja) 2000-02-25 2012-07-18 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ハイブリッド血管内皮成長因子ＤＮＡｓおよびタンパク質に関与する物質および方法
AU2001268149B2 (en) * 2000-06-01 2005-08-18 University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
TWI257307B (en) 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair
MXPA02003434A (es) 2000-08-04 2002-09-02 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
DK2314293T3 (en) 2001-01-16 2017-04-18 Vascular Therapies Llc IMPLANTABLE DEVICE CONTAINING RESORBABLE MATERIAL MATERIAL AND RAPAMYCINE FOR PREVENTION OR TREATMENT OF VASCULOPROLIFERATIVE DISEASES
MXPA03009408A (es) 2001-04-13 2004-01-29 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
FI20010898A0 (fi) * 2001-04-30 2001-04-30 Ylae Herttuala Seppo Ekstrasellulaarinen superoksididismutaasi (EC-SOD) geeniterapia restenoosoin ehkäisemiseksi
GB0120690D0 (en) 2001-08-24 2001-10-17 Novartis Ag Organic compounds
BR0309676A (pt) * 2002-04-30 2005-02-22 Fit Biotech Oyl Plc Dispositivo médico
PL195457B1 (pl) * 2002-08-05 2007-09-28 Zaklady Farm Polpharma Sa Kaseta ekspresyjna, dwucistronowy wektor plazmidowy, środek farmaceutyczny oraz ich zastosowanie
US20070254956A1 (en) * 2003-10-29 2007-11-01 Koichi Shudo Medicament for Therapeutic and/or Preventive Treatment of Restenosis or Reocclusion After Vascular Recanalization Operation
JP4832290B2 (ja) * 2004-03-18 2011-12-07 健輔 江頭 薬剤・遺伝子溶出型ステント
EP1919944B1 (en) 2005-08-15 2011-03-23 Vegenics Pty Ltd Modified vegf and pdgf with improved angiogenic properties
CA2663547C (en) 2006-09-22 2020-08-25 Orthologic Corp. Method of treating endothelial dysfunction
JP2011512408A (ja) 2008-02-19 2011-04-21 セラドン・コーポレーション 心筋層へのウイルスベクターの取り込みを増大させるための組成物
WO2012088563A1 (en) * 2010-11-24 2012-07-05 Vegenics Pty Limited Vegfr-2-specific forms of vegf-d and vegf-c and uses thereof
CA3131428A1 (en) * 2019-03-29 2020-10-08 Jerald Wayne CURRAN Systems and methods for left ventricular unloading in biologic therapy or vectored gene therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033917A1 (en) * 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
DE69734359T2 (de) * 1996-08-23 2006-07-06 Ludwig Institute For Cancer Research Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d)
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
WO1998049300A2 (en) * 1997-04-25 1998-11-05 Collateral Therapeutics Truncated vegf-related proteins

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101361988B (zh) * 2008-09-12 2011-12-21 西南交通大学 一种具有生物相容性的血管支架或心脏瓣膜表面涂层的制备方法
CN108640994A (zh) * 2018-06-28 2018-10-12 浙江众意生物科技有限公司 一种vegf-c单克隆抗体及试剂盒
CN119454907A (zh) * 2025-01-09 2025-02-18 浙江大学 Vegf-c156s在制备减轻静脉移植物狭窄的药物中的应用

Also Published As

Publication number Publication date
JP5231587B2 (ja) 2013-07-10
CA2340593C (en) 2012-05-08
WO2000024412A3 (en) 2000-08-03
EP1126870A2 (en) 2001-08-29
NO20012017D0 (no) 2001-04-24
NO20012017L (no) 2001-06-26
DE69920031D1 (de) 2004-10-14
AU768330B2 (en) 2003-12-11
DE69920031T2 (de) 2005-09-22
PT1126870E (pt) 2005-01-31
NZ510121A (en) 2003-02-28
WO2000024412A2 (en) 2000-05-04
EP1126870B1 (en) 2004-09-08
ATE275417T1 (de) 2004-09-15
JP2002528420A (ja) 2002-09-03
AU1314700A (en) 2000-05-15
JP4769929B2 (ja) 2011-09-07
CA2340593A1 (en) 2000-05-04
ES2229788T3 (es) 2005-04-16
JP2011173874A (ja) 2011-09-08

Similar Documents

Publication Publication Date Title
CN1338943A (zh) 利用vegf－c或vegf－d基因或蛋白预防再狭窄
US6958147B1 (en) Use of VEGF-C to prevent restenosis
CN101610793B (zh) 长效药物制剂
Bonadio et al. Gene therapy for tissue repair and regeneration
EP1888101B1 (en) Compositions and methods for lipo modeling
AU779619B2 (en) Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
EP0998307B1 (en) METHOD FOR TREATING VASCULAR PROLIFERATIVE DISEASES WITH p27 AND FUSIONS THEREOF
CN1226835A (zh) 用于伤口愈合的体内基因转移
JPH10309191A (ja) 血管内皮細胞増殖因子の製造
WO1997011720A1 (en) Methods for treating cancers and restenosis with p21
JP2003516180A (ja) 医療用装置
JP2002502608A (ja) 血管新生促進因子である血管内皮細胞成長因子：ｖｅｇｆの変異体
JP2005521643A (ja) アンジオポエチン様タンパク質３Ａｎｇｐｔｌ３含有組成物とその使用方法
JP2004500844A (ja) Ｔｗｅａｋアゴニストおよび血管形成因子を使用する、新血管新生を促進するための方法
Drucker Epithelial cell growth and differentiation. I. Intestinal growth factors
Mujagic et al. Induction of aberrant vascular growth, but not of normal angiogenesis, by cell-based expression of different doses of human and mouse VEGF is species-dependent
US20030139333A1 (en) Methods and compositions for promoting angiogenesis
CN103260649A (zh) 长效药物制剂
EP1075520A1 (en) Introduction of naked dna or rna encoding non-human vertebrate peptide hormones or cytokines into a non-human vertebrate
CN112190709A (zh) 基质细胞蛋白ccn5组合物及其应用
JP2005506279A (ja) 血管新生を促進する方法及び組成物
EP1568375A1 (en) Use of VEGF-C or VEGF-D gene or protein to prevent restenosis
CN100556455C (zh) 一种用于预防和治疗i型糖尿病的药物复合物及其应用
WO2002100324A2 (en) Compositions and methods for the repair and construction of bone and other tissue
AU2004201020A1 (en) Use of VEGF-C or VEGF-D Gene or Protein to Prevent Restenosis

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication